IDEAYA Biosciences’ Post

View organization page for IDEAYA Biosciences, graphic

12,906 followers

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer: https://lnkd.in/gnjZ4A94

4 Comments

Michael D.

Experienced Pharma/Biotech Drug Discovery Executive

Another clinical molecule discovered by one of the best discovery teams in Biotech! Congratulations to all the IDE397 team members!

20 Reactions

Darren Nelson 🚀 (We're hiring)

Innovative Leadership in Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies.

That's fantastic news, IDEAYA Biosciences! The positive interim Phase 2 data for IDE397, your potential first-in-class MAT2A inhibitor in MTAP-Deletion Urothelial and Lung Cancer, is truly promising. Looking forward to seeing how this innovation continues to advance cancer treatment. Keep up the excellent work! 🚀💼

2 Reactions

Zhonghua Pei

Senior VP of Chemistry & DMPK at Neuron23, Inc

Go IDE397!!!

4 Reactions

Joe Armstrong

Chief Marketing Officer at TCG GreenChem, Inc. Global Head of Business Development

congratulations!

See more comments

To view or add a comment, sign in

More Relevant Posts

Guillermo Potdevin Stein, MD PhD

Radiation Oncologist / Oncólogo Radioterápico SRS, fSRS, SBRT, Lung SBRT, DIBH, Gating, multiple Brain Metástasis, Breast Ultra-Hypofractionation, TrueBeam-Novalis
11mo Edited
Report this post
Full dose SBRT in combination with mediastinal chemoradiation for locally advanced, non-small cell lung cancer: A practical guide for planning, dosimetric results from a phase II study, and a treatment planning guide for the phase III NRG Oncology LU-008 trial. https://lnkd.in/edWZVTjE

1 Comment
Like Comment
To view or add a comment, sign in
David J. Heredia Vázquez

Oncologo Médico con Alta Especialidad en tumores torácicos. Senior Medical Scientific Liason Oncology
3mo
Report this post
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer : ALINA Trial Published April 10, 2024 N Engl J Med 2024;390:1265-1276 DOI: 10.1056/NEJMoa2310532
Like Comment
To view or add a comment, sign in
Cancers MDPI

4,546 followers
4mo
Report this post
📢Today we share the #Review "Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability" 🧐by Beatrice Borelli, Carlotta Antoniotti, et al. Find the full paper here👉 https://lnkd.in/eJZ-3QvF Keywords: immune-checkpoint inhibitors; deficient mismatch repair; high microsatellite instability
Like Comment
To view or add a comment, sign in
Salma Nazar

Medical Student at UOS 🩺 Future Surgeon
1mo
Report this post
🔊 EXCITING NEWS! 🔊 According to the Prostate Cancer Foundation just a few hours ago, researchers have revealed promising new treatment for advanced metastatic castration-resistant prostate cancer (abbreviated mCRPC)! This news came in light of positive results achieved from a clinical trial using CAR T-cell therapy. To read more about this revolutionary treatment: https://lnkd.in/dmsuvapx
Like Comment
To view or add a comment, sign in
Lilly Medical US

14,351 followers
4mo
Report this post
At #ELCC24, we're presenting additional analysis from LIBRETTO-001, a phase I/II study of a RET kinase inhibitor in patients with RET fusion-positive non-small cell lung cancer (#NSCLC). Click here to learn more about our presentations at this year's meeting: https://e.lilly/4ajw0a4 #LungCancer #LCSM #CancerResearch
Like Comment
To view or add a comment, sign in
International Journal of Radiation Biology

486 followers
2mo
Report this post
The ATR inhibition by Elimusertib enhances the radiosensitivity of MDA-MB-231 triple negative breast cancer in vitro https://bit.ly/4bkBH8i
Like Comment
To view or add a comment, sign in
Tina W.
6mo
Report this post
Priority Review in process for the sBLA, with a 5/9/2024 PDUFA for Pfizer/Genmab's ADC Tivdak in 2L recurrent or metastatic cervical cancer #ADC #AntibodyDrugConjugates #Pfizer #Genmab #Oncology #Cancer #CervicalCancer #RegulatoryAffairs #Pharma #Innovation #Healthcare

Pfizer

5,920,186 followers
6mo Edited

BREAKING: FDA accepts for priority review a sBLA application for our investigational antibody-drug conjugate for the treatment of recurrent or metastatic cervical cancer, together with our partner Genmab. Learn more: https://lnkd.in/eWPsgQaZ

Read More About Today’s Announcement
Like Comment
To view or add a comment, sign in
Genprex, Inc.

3,562 followers
2mo
Report this post
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: https://ow.ly/CxZt50RFBZH

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - Genprex
Like Comment
To view or add a comment, sign in
OncologyTheranosticsCommittee EANM

Medical Doctor na European Association of Nuclear Medicine (EANM)
2mo
Report this post
Joint EANM‑SNMMI guideline on the role of 2‑[18F]FDG PET/CT in no special type breast cancer (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA) - Summary of the 2-[18F]FDG PET/CT recommendations according to the clinical scenario in NST breast cancer
Like Comment
To view or add a comment, sign in
Cancers MDPI

4,546 followers
3mo
Report this post
📜Today we share the #Review "The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance" 🧐by Mary Abdelmalak et al. Access the full paper here👉 https://lnkd.in/d6VcntUS Keywords: abemaciclib; advanced breast cancer; CDK4/6 inhibitor
Like Comment
To view or add a comment, sign in

12,906 followers

View Profile Follow

IDEAYA Biosciences’ Post

More Relevant Posts

Read More About Today’s Announcement

Explore topics